top of page
REGISTRY
The International Radiosurgery Oncology Consortium for Kidney (IROCK) collaborates on research into stereotactic ablative radiotherapy (SABR) for primary renal cell carcinoma (RCC). The primary purpose of the IROCK Registry is to evaluate the time between SABR treatment and recurrence (when cancer returns after treatment) that occurs in the area of the initial tumour, in patients with RCC. The secondary objective of the study will assess efficacy and survival outcomes.
The IROCK Registry is extremely grateful to the Lo's Family Charity Fund Limited
for providing the registry with secure funding for five years via a generous donation.
bottom of page